← All companies
$4.53
−1.95% (−$0.09) on the day
Close Nov 13, 2026
Market cap
$2.25M
1 month
−29.44%
52-week range
—
Last month
Why we cover it
Developing CMND-100, based on the compound MEAI, for alcohol use disorder, with patient dosing underway in an early-stage trial in Israel. Also files patents on combinations of LSD, ketamine and ibogaine.
Financials
| Cash & equivalents | $3.92M | as of Oct 31, 2025 · 20-F |
| Research & development | $2.06M | year ended Oct 31, 2025 · 20-F |
| Net income (loss) | −$3.86M | year ended Oct 31, 2025 · 20-F |
From the company's SEC filings. See all filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| CMND-100 for Alcohol Use Disorder | MEAI | Phase I/IIa (patient dosing underway) |
Patents Patent tracker
| Holder | Compounds | Granted | Pending | Expire |
|---|---|---|---|---|
| Clearmind Medicine Inc | LSD, Ketamine, Ibogaine, MEAI | 32 | 3 | 2037 |
News (1)
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.